Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Managed Care November 2005	Plans Change Tactics As Costs Keep Rising For Specialty Drugs With specialty drug costs continually increasing, CuraScript expects to see a significant shift in the percentage of plans exclusively classifying specialty drugs under the medical benefit.
Managed Care July 2006	Specialty Anti-Inflammatories See Huge Increase in Utilization Americans spent 34% more for specialty anti-inflammatory agents used to treat rheumatoid arthritis in 2005 than any other specialty drug category.
Managed Care August 2004 Alan Lotvin	Specialty Pharmacy Presents Unique Set of Challenges Only a small percent of a typical health plan's population takes medicine for conditions outside the generalist's scope. But it's a big portion of the drug bill.
Managed Care September 2005 John Carroll	Plans Struggle for Control of Specialty Pharma Costs Biotech drugs are a quickly growing component of health plan budgets. Here are the latest management techniques.
The Motley Fool June 12, 2006 Brian Gorman	Biogeneric Payoff? A new report indicates that spending on specialty drugs increased 17.5% in 2005. This growth bodes well for makers of biotech drugs, which make up a large portion of the specialty drug category. Investors, take note.
Managed Care February 2005	Biggest increases in specialty drug costs seen in rheumatologic, cancer, and hemophilia agents Medco reports that of the top seven contributors to specialty drug costs, agents for rheumatologic conditions (80.6 percent), cancer (33.2 percent), and hemophilia (28.4 percent) demonstrated the greatest percent change in cost from 2002 to 2003.
Managed Care April 2002 Paula Sirois	HMOs Should Prepare Now To Get Handle on Injectables With more than 360 biotech products in the pipeline, high-cost injectable drugs are about to flood the market. How will we control the expenditure?
Managed Care September 2006 Martin Sipkoff	Specialty Pharmacy Grows As Cost-Control Option As the population ages, specialty pharmacy is becoming a unique, profitable, and invaluable delivery system. Plans are increasingly turning to specialty pharmacies to provide the expertise they lack.
Managed Care May 2004	Biologics Among Fastest Growers Managed care plans and pharmacy benefit managers can benefit from the strong generic presence in the market, but also face challenges relating to biotech drugs.
Managed Care March 2008	Specialty Drug Spending to Double by 2010 Additional indications for existing products, rather than new products, account for the bulk of increased specialty drug use.
The Motley Fool March 4, 2005 Tom Taulli	In the Express Scripts Lane Express Scripts' strong results bring a much-needed lift to health-care investors.
The Motley Fool July 30, 2009 Brian Orelli	A Good Business Model for Bad Times Some businesses benefit when people are hurting. It's a beautiful time to be a pharmacy benefit manager, since that business model essentially results in them making more money when their customers save money.
Managed Care February 2005 Mark Zitter	Managing Drugs for Rare Genetic Diseases: Trends and Insights Evaluates recent trends and challenges in health system management of exceedingly rare genetic diseases, from the perspective of the manufacturer, managed care organization, physician, and actuary.
The Motley Fool April 29, 2010 Brian Orelli	A Prescription to Investigate Further Let's not worry just yet about Medco's margins.
CIO September 26, 2013 Stephanie Overby	Big Data Project Cuts Prescription Costs Express Scripts analytics portal helps doctors prescribe more cost-effective medicines.
Managed Care December 2006	The Formulary Files Four core strategies are used to manage outpatient specialty pharmacy costs.
The Motley Fool July 23, 2009 Brian Orelli	This Too Shall Pass ... Like a Kidney Stone Demand outstrips supply? Boo-hoo. Lowered guidance because a company can't make enough to keep up with demand. Example: Genzyme
The Motley Fool July 6, 2007 Mike Cianciolo	Walgreen: The New Deal Maker Walgreen announces its latest acquisition as it tries to keep pace with the competition. Investors, take note.
The Motley Fool August 24, 2011 Brandon Glenn	Cardinal Health Sees Opportunity (but Faces Challenges) in Specialty Drugs Is Cardinal up for the challenge?
The Motley Fool March 6, 2009 Brian Orelli	Don't Let It Go! Health insurer WellPoint is trying to sell its pharmacy business management segment. Is it the right move for them for right now?
Chemistry World April 2, 2015 Emma Stoye	Horizon to acquire orphan drugs in $1.1bn Hyperion takeover Horizon will gain two rare disease drugs: Ravicti (glycerol phenylbutyrate) and Buphenyl (sodium phenylbutyrate), which are used to treat urea cycle disorder.
The Motley Fool August 10, 2004 Brian Gorman	Biotech Cost Control Will the high cost of therapies slow sales in the sector? Investors can avoid problems by paying close attention to companies' pipelines and reimbursement trends.
The Motley Fool August 1, 2008 Brian Orelli	Express Scripts Gets More Generic Pharmacy benefits manager Express Scripts may not have grown the top line by much in the second quarter, but using more generic drugs had a positive effect on the bottom line.
Pharmaceutical Executive November 1, 2012 Lauri Mitchell	Who Pays for Specialty Medicines? Providers and patients fish for that delicate balance between access and abandonment.
BusinessWeek March 7, 2005 Amy Barrett	A Drug Company On Growth Hormones By adding Accredo to its portfolio, Medco gains a strong presence in the area of specialty drugs. Investors sent Medco's stock down slightly on news of the deal. But they give company chief David B. Snow Jr. credit for putting Medco in a position to capitalize on new opportunities.
The Motley Fool February 28, 2011 Brian Orelli	Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on.
Managed Care September 2007 Frank Diamond	Pay for Performance in Pharmacy Is More Theory Than Reality Even if the the goal of pay-for-performance pharmacy programs is unattainable in this country, working toward it might produce interesting experiments in cost efficiency.
Managed Care June 2006 John Carroll	When New Drugs Are Costly, How High to Raise Copays? As some pretty costly, yet very useful, drugs are introduced, will new formulary designs deny access to needy patients?
Pharmaceutical Executive February 1, 2014 Jill Wechsler	Drug Coverage, Costs Under Scrutiny Benefits offered by insurance plans on health exchanges and through Medicare are raising concerns about patient access to needed therapies
The Motley Fool February 25, 2010 Brian Orelli	An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies.
Chemistry World September 11, 2012 Maria Burke	Orphan drugs set for 'tremendous growth' A new report by Thomson Reuters offers clear confirmation that developing drugs for rare, or orphan, diseases is economically attractive, despite the smaller patient pool.
The Motley Fool December 21, 2004 Charly Travers	Invest With Fewer Side Effects Averse to risk? Check out these nontraditional drug companies: Biogen Idec... Elan... Salix Pharmaceuticals... Atrix Laboratories... etc.
Managed Care July 2003 John Carroll	CMS Move Threatens To Put Orphan Drugs Out in Cold Have drug companies lost the incentive to develop products for small populations? What's managed care's stake?
Managed Care April 2001	Employers easing prescription limitations? Some older medications once viewed by employers as "lifestyle" drugs when making benefit decisions are slowly gaining recognition as important components of primary care...
Managed Care June 2006	Medical Directors Cast Wary Eye On Cost of Biologics Given the exploding costs of specialty products and new technologies, MCOs are exercising tighter control over precertification of products and services.
The Motley Fool August 1, 2006 Selena Maranjian	Prescription for Prescription Bargains Did you know that your medications might be cheaper around the corner? Another way to offset your net expenses on medications is to make some money on drugs -- by investing in drug-related firms.
Pharmaceutical Executive June 9, 2014 Kleinrock & Noor	Pharm Exec's Pharma 50 2014 For those companies in this year's Pharm Exec Top 50, meeting the accelerating market demand for specialty products has become an acute strategic imperative.
Managed Care May 2003 Wayne Miller	Higher Drug Copays Now Might Cause Problems Later The long-term impact of noncompliance must be considered before copayments are increased. This is especially true where chronic conditions are concerned.
Managed Care January 2002	Employers struggle to preserve pharmacy benefit In an effort to protect the pharmacy benefit for employees, companies are using a variety of techniques to manage expenditures...
The Motley Fool May 6, 2008 Brian Orelli	Free Drugs Free over-the-counter drugs are a win-win for health insurers and their members.
Managed Care March 2006	Study: No Need To Burden Consumers To Cut Drug Bill A study by Express Scripts shows that changing the prescription benefit copayments can reduce costs by encouraging more use of generic drugs. All without shifting costs to consumers.
Managed Care September 2003 Thomas Morrow	Managed Care Strategy: Create Competition In Expanding Biotech Field The biotech field is booming, and insurers are scrambling to find ways to deal with the high costs of new "biologic" treatments. One strategy is to try to create more competition among the producers of biotech drugs.
The Motley Fool August 30, 2004 W.D. Crotty	Warning Bells for Specialty Pharmacy? Accredo Health lowers earnings guidance for 2005.
The Motley Fool February 23, 2006 Stephen D. Simpson	Express Scripts Overdue for a Pause This pharmacy benefits manager is posting very good growth and has room for improvement, but what about the stock price?
Managed Care May 2001	Old Ideas About Formulary Structure Gone as Humana Tests 4-Tier Model Humana is phasing in a four-tier formulary that categorizes prescription drugs by costs, rather than generic or brand status. The higher the drug's acquisition cost -- regardless of whether it's a branded or generic product -- the higher the tier it lands in...
Managed Care October 2007	The Formulary Files Retirees stop taking drugs when annual benefit runs out.
Managed Care January 2008	Too Few Programs to Manage MS? Disease management programs for patients with multiple sclerosis improve outcomes and adherence, reduce disability, and contains cost, but there are not enough of them in existence.
The Motley Fool March 22, 2010 Brian Orelli	Health-Care Reform Passes! Here's Where to Invest Now Some healthy suggestions for your portfolio.
The Motley Fool December 6, 2007 Selena Maranjian	Your Drugs Are in the Mail Order medications online and save. According to a study by the Lewin Group, mail-order pharmacies, such as Medco and Express Scripts, can save you as much as 10% overall.
The Motley Fool January 3, 2006 Stephen D. Simpson	Walgreen Reaps Rewards of Rx The nation's top pharmacy keeps on rolling, but investors might want to keep an eye on the new ventures.